1-8 of 8
Brett P. Monia
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract B197: Selective depletion of YAP1 with next-generation antisense oligonucleotides leads to immune cell infiltration and tumor regression in mouse models of HCC

Youngsoo Kim, Joanna Schmidt, Minji Jo, Jing Yi, Tianyuan Zhou, Xiaolin Luo, Sun Young Yim, Ju-Seog Lee, Randy L. Johnson, Brett P. Monia, Gordon Mills, A. Robert MacLeod
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): B197.
https://doi.org/10.1158/1535-7163.TARG-17-B197
Published: 01 January 2018
View article titled, Abstract B197: Selective depletion of YAP1 with next-generation antisense oligonucleotides leads to immune cell infiltration and tumor regression in mouse models of HCC
Journal Articles

Abstract A73: Antisense oligonucleotides targeting ENO2 have selective anti-proliferative effects in glioblastoma cell with 1p36 genomic loss

Maria Shahmoradgoli, Curt Mazur, Youngsoo Kim, Brett P Monia, A. Robert Macleod, Florian M Muller, Christopher E Hart
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): A73.
https://doi.org/10.1158/1535-7163.TARG-15-A73
Published: 01 December 2015
View article titled, Abstract A73: Antisense oligonucleotides targeting ENO2 have selective anti-proliferative effects in glioblastoma cell with 1p36 genomic loss
Journal Articles

Abstract PR12: Discovery and preclinical evaluation of cEt-modified KRAS antisense oligonucleotide inhibitors

Alexey S. Revenko, Sarah J. Ross, Lyndsey L. Hanson, Rebecca Ellston, Chris May, Sanjay K. Pandey, Linda K. Buckett, Stephanie K. Klein, Mitchell Revill, Kevin Hudson, Brett P. Monia, David C. Blakey, Paul Lyne, Allan R. MacLeod
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): PR12.
https://doi.org/10.1158/1535-7163.TARG-15-PR12
Published: 01 December 2015
View article titled, Abstract PR12: Discovery and preclinical evaluation of cEt-modified KRAS antisense oligonucleotide inhibitors
Journal Articles

Abstract A259: Characterization of next generation (Gen2.5) KRAS antisense inhibitors in NSCLC, PDAC, and CRC models.

Alexey S. Revenko, Gourab Bhattachrjee, Chris May, Brett P. Monia, A. Robert MacLeod
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): A259.
https://doi.org/10.1158/1535-7163.TARG-13-A259
Published: 01 November 2013
View article titled, Abstract A259: Characterization of next generation (Gen2.5) KRAS antisense inhibitors in NSCLC, PDAC, and CRC models.
Journal Articles

Abstract C136: Exploring the functional contribution of STAT3 activity in tumor and tumor-associated stromal cells with species-selective generation 2.5 antisense oligonucleotides in preclinical cancer models.

Jeff Hsu, Guobin He, Gourab Bhattacharjee, Tianyuan Zhou, Youngsoo Kim, Brett P. Monia, Robert MacLeod
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): C136.
https://doi.org/10.1158/1535-7163.TARG-11-C136
Published: 12 November 2011
View article titled, Abstract C136: Exploring the functional contribution of STAT3 activity in tumor and tumor-associated stromal cells with species-selective generation 2.5 antisense oligonucleotides in preclinical cancer models.
Journal Articles

Transcription Factor Stat5 Knockdown Enhances Androgen Receptor Degradation and Delays Castration-Resistant Prostate Cancer Progression In vivo

Christian Thomas, Amina Zoubeidi, Hidetoshi Kuruma, Ladan Fazli, Francois Lamoureux, Eliana Beraldi, Brett P. Monia, A. Robert MacLeod, Joachim W. Thüroff, Martin E. Gleave
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (2): 347–359.
https://doi.org/10.1158/1535-7163.MCT-10-0850
Published: 08 February 2011
View article titled, Transcription Factor Stat5 Knockdown Enhances Androgen Receptor Degradation and Delays Castration-Resistant Prostate Cancer Progression <em>In vivo</em>
Open the PDF for Transcription Factor Stat5 Knockdown Enhances Androgen Receptor Degradation and Delays Castration-Resistant Prostate Cancer Progression <em>In vivo</em> in another window
Includes: Supplementary data
Journal Articles

Disruption of WT1 gene expression and exon 5 splicing following cytotoxic drug treatment: Antisense down-regulation of exon 5 alters target gene expression and inhibits cell survival

Jane Renshaw, Rosanne M. Orr, Michael I. Walton, Robert te Poele, Richard D. Williams, Edward V. Wancewicz, Brett P. Monia, Paul Workman, Kathryn Pritchard-Jones
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2004) 3 (11): 1467–1484.
https://doi.org/10.1158/1535-7163.1467.3.11
Published: 01 November 2004
View article titled, Disruption of <em>WT1</em> gene expression and exon 5 splicing following cytotoxic drug treatment: Antisense down-regulation of exon 5 alters target gene expression and inhibits cell survival
Open the PDF for Disruption of <em>WT1</em> gene expression and exon 5 splicing following cytotoxic drug treatment: Antisense down-regulation of exon 5 alters target gene expression and inhibits cell survival in another window
Journal Articles

Enhanced oxaliplatin-induced apoptosis following antisense Bcl-xl down-regulation is p53 and Bax dependent: Genetic evidence for specificity of the antisense effect

Richard L. Hayward, Janet S. Macpherson, Jeff Cummings, Brett P. Monia, John F. Smyth, Duncan I. Jodrell
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2004) 3 (2): 169–178.
https://doi.org/10.1158/1535-7163.169.3.2
Published: 25 February 2004
View article titled, Enhanced oxaliplatin-induced apoptosis following antisense Bcl-xl down-regulation is p53 and Bax dependent: Genetic evidence for specificity of the antisense effect
Open the PDF for Enhanced oxaliplatin-induced apoptosis following antisense Bcl-xl down-regulation is p53 and Bax dependent: Genetic evidence for specificity of the antisense effect in another window